Anthos Therapeutics, Inc.
Clinical trials sponsored by Anthos Therapeutics, Inc., explained in plain language.
-
New blood thinner aims to reduce bleeding risk in heart patients
Disease control OngoingThis study is testing whether a new investigational blood thinner called abelacimab causes less bleeding than the standard drug rivaroxaban. It involves about 1,300 adults with atrial fibrillation who are at moderate-to-high risk of stroke. The main goal is to see which medicatio…
Phase: PHASE2 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 05:12 UTC
-
Monthly shot aims to outperform daily injections for Cancer-Related blood clots
Disease control OngoingThis study is testing if a new monthly injection (abelacimab) works better and is safer than a standard daily injection (dalteparin) for preventing dangerous blood clots from coming back. It is for adults with specific cancers of the stomach, intestines, or urinary system who hav…
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC